Medically reviewed by Kelly Wood, MD Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative therapeutic approaches capable of addressing multiple metabolic pathways ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Sitagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide to ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, ...

Zepbound belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. It contains the active ingredient tirzepatide and comes ...